ddn Online

The Blog of Drug Discovery News

More pink slips

Well, the topic is not a new one, and ddn Chief Editor Amy Swinderman did a bang-up job talking about the pharma layoff issue a month-and-a-half ago (click here), but it’s starting to feel like we’re gearing up for another round of these things.

Just over a week ago I posted a story about Roche restructuring/layoff plans (at our web site), and now this:

__________________________________________

Novartis Pharmaceuticals Corp. to cut 1,400 U.S. jobs

EAST HANOVER, N.J.—Novartis Pharmaceuticals Corp. announced Nov. 30 that it is restructuring its General Medicines field force in the United States to reflect changes in the product portfolio and align resources with strategic growth priorities. The company will reduce its General Medicines field force by approximately 1,400 positions. These changes will be effective Jan. 1, 2011.

The product portfolio within the Novartis General Medicines business is changing due to pending patent expirations and pipeline products. There are new product launches expected within the Primary Care business and significant growth momentum within the Specialty Care business that will drive long-term success. Given these changing dynamics within the portfolio, it is critical to realign the General Medicines field force to sharpen focus on the greatest opportunities for growth. The restructuring is expected to result in a one-time cost of approximately $85 million.

“NPC has a robust pipeline and the future growth potential for our organization remains strong. Proactively evolving our business model will enable us to focus our resources on key launch products and capture opportunities in both primary care and specialty medicines,” said Andy Wyss, head of Novartis Pharma North America and president of Novartis Pharmaceuticals Corp.

All reductions will, according to the company, be handled in “a manner consistent with the Novartis commitment to fair and respectful treatment of associates. Outplacement and other support services will be available to impacted associates as well as redeployment opportunities, where they exist, within the Novartis Group of companies.”

__________________________________________

Keep those résumés updated, everyone…

.

Advertisements

December 1, 2010 - Posted by | Corporate | , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: